Related Experiment Videos
Summary
Gilles de la Tourette syndrome, a neurodevelopmental condition affecting 1% of children, involves basal ganglia-cortical dysfunction. Management includes behavioral therapies and medications, with deep brain stimulation as an emerging option.
Area of Science:
- Neuroscience
- Genetics
- Pediatrics
Background:
- Gilles de la Tourette syndrome (GTS) affects approximately 1% of children, presenting with diverse severity and comorbidities.
- Recent decades have yielded significant progress in understanding GTS genetics and neurobiology.
Observation:
- Neuroimaging and neurophysiological studies suggest GTS is a neurodevelopmental disorder.
- Dysfunction in basal ganglia-cortical interactions is a key feature, now explored in animal models.
Findings:
- Evidence supports various treatments, though management remains challenging.
- First-line treatments include neuroleptics, other medications, and specialized behavioral therapies.
- Deep brain stimulation is an evolving therapeutic avenue for GTS.
Implications:
- This review synthesizes current knowledge on tic phenomenology, assessment, and management of GTS.
- Atypical cases are examined to delineate the clinical spectrum and limitations of GTS.
- Advances in understanding neurobiology and treatment options offer improved management strategies for patients with GTS.